Metis Global Partners LLC Acquires New Shares in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Metis Global Partners LLC acquired a new position in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 29,319 shares of the company’s stock, valued at approximately $84,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company boosted its holdings in shares of Organogenesis by 15.4% in the second quarter. The Manufacturers Life Insurance Company now owns 30,984 shares of the company’s stock valued at $87,000 after buying an additional 4,130 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Organogenesis by 11.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 50,951 shares of the company’s stock valued at $145,000 after acquiring an additional 5,359 shares in the last quarter. Mackenzie Financial Corp boosted its stake in Organogenesis by 46.1% in the 2nd quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock worth $68,000 after purchasing an additional 7,678 shares during the period. Pallas Capital Advisors LLC increased its holdings in Organogenesis by 70.8% during the 3rd quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company’s stock worth $63,000 after purchasing an additional 9,048 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its stake in shares of Organogenesis by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 269,741 shares of the company’s stock valued at $755,000 after purchasing an additional 9,054 shares during the period. 49.57% of the stock is currently owned by institutional investors.

Organogenesis Stock Up 3.6 %

ORGO stock opened at $4.08 on Wednesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The stock has a market capitalization of $540.93 million, a P/E ratio of -66.83 and a beta of 1.60. Organogenesis Holdings Inc. has a fifty-two week low of $2.16 and a fifty-two week high of $4.70. The business has a 50-day moving average of $3.05 and a 200-day moving average of $2.84.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Tuesday, November 12th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The firm had revenue of $115.18 million for the quarter, compared to analysts’ expectations of $109.59 million. During the same quarter in the previous year, the business posted $0.02 EPS. On average, sell-side analysts anticipate that Organogenesis Holdings Inc. will post -0.12 earnings per share for the current fiscal year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.